There are currently 50 active clinical trials seeking participants for Migraine research studies. The states with the highest number of trials for Migraine participants are Florida, California, Texas and New York.
Inhaled IAV vs Inhaled Eucalyptus for the Treatment of Nausea With Acute Migraine
NCT05175521
Recruiting
The goal of this study is to compare the efficacy and adverse events of inhaled isopropyl alcohol vapor (IAV) versus placebo (inhaled eucalyptus scent (IES) (1:20 dilution in mineral oil) for treating nausea associated with acute migraine attacks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/27/2025
Locations: HonorHealth Bob Bové Neuroscience Institute, Scottsdale, Arizona
Conditions: Migraine
Register for Updates
External Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy
NCT06788977
Recruiting
This online registry aims to understand the potential benefits and safety of external trigeminal nerve stimulation for the treatment of migraine in pregnant women. Women do not need to use external trigeminal nerve stimulation or any other form of migraine treatment to participate in the registry. The main question it aims to answer is: Is external trigeminal nerve stimulation a safe and effective option for migraine treatment during and after pregnancy? There are no required changes in migra... Read More
Gender:
FEMALE
Ages:
Between 18 years and 44 years
Trial Updated:
01/17/2025
Locations: https://public.smart-trial.co/#/public/649d77f0e8f8d0fb993d0c61/6626f6a04f0a3c7dd0860e14/662726d84f0a3c7dd08aeaa0/signup?lang=en-us&enforceLanguage=true, Darien, Connecticut
Conditions: Pregnancy, Migraine, Headache, Postpartum, Depression, Anxiety
Register for Updates
Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy
NCT05158894
Recruiting
Migraine is a common neurological disorder typically characterized by attacks of throbbing or pulsating headache on one side of the head of moderate to severe pain intensity. The purpose of this study is to evaluate fetal, maternal, and infant outcomes through 12 months of age among women exposed to Ubrelvy or Qulipta during pregnancy, as well as in 2 comparator groups. Ubrelvy (ubrogepant) and Qulipta (atogepant) are approved drugs for the acute treatment of migraine in adults. Approximately 6... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Iqvia /Id# 266904, Durham, North Carolina
Conditions: Migraine
Register for Updates
Mind Body Balance for Pediatric Migraine
NCT04715685
Recruiting
This study uses a factorial research design to evaluate a nurse delivered mind body intervention using different doses of 3 treatment components to determine the optimized treatment for headache day reduction.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
01/02/2025
Locations: University of Colorado/Children's Hospital Colorado, Aurora, Colorado +1 locations
Conditions: Headache, Headache Disorders, Headache, Migraine, Migraine, Migraine Disorders, Migraine With Aura, Migraine Without Aura, Chronic Migraine
Register for Updates
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics
NCT06624137
Recruiting
The goal of this observational study is to learn how the brain's information processing changes during and following administration of serotonergic psychedelics (psilocybin, N,N-Dimethyltryptamine/DMT, Lystergic Acid Diethylamide/LSD, etc.) for people with and without mental illness receiving serotonergic psychedelics through any clinical trial at Yale University. The main questions it aims to answer are: 1. Do serotonergic psychedelics cause the brain to rely on new information more than previ... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/12/2024
Locations: Connecticut Mental Health Center, Hamden, Connecticut +1 locations
Conditions: OCD, Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD), Healthy Volunteer, Migraine, PTSD, PTSD - Post Traumatic Stress Disorder, Addiction, Tobacco Use Disorder, Obsessive Compulsive Disorder (OCD), Opioid Use Disorder
Register for Updates
RELAXaHEAD for Headache Patients (Phase III)
NCT06077838
Recruiting
This study is a fully powered, remote randomized control trial to evaluate RELAXaHEAD in people with migraine.
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
10/08/2024
Locations: NYU Langone Health, New York, New York
Conditions: Migraine
Register for Updates
Aimovig Pregnancy Exposure Registry
NCT06150781
Recruiting
The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed to erenumeb-aooe.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
10/02/2024
Locations: IQVIA Virtual Site, Durham, North Carolina
Conditions: Migraine
Register for Updates
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
NCT06473597
Recruiting
Rimegepant (Nurtec) is an orally administered small molecule CGRP receptor antagonist with efficacy in the acute treatment of migraine. Rizatriptan benzoate (MAXALT), is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist. Rizatriptan binds with high affinity to human cloned 5-HT1B and 5-HT1D receptors which leads to activation of these receptors results in cranial vessel constriction, inhibition of neuropeptide release and reduced transmission in trigeminal pain pathways with resu... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/27/2024
Locations: Maimonides Medical Center, Brooklyn, New York
Conditions: Migraine
Register for Updates
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
NCT06401642
Recruiting
Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of migraine attacks amongst participants who are using calcitonin gene-related peptide (CGRP) migraine preventive treatments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2024
Locations: Mayo Clinic in Arizona, Phoenix, Arizona
Conditions: Migraine
Register for Updates
Objectively Diagnose and Monitor Treatment of Light Sensitivity
NCT03694626
Recruiting
The purpose of this project is to provide a new framework for diagnosing and monitoring treatment of light sensitivity and headache by objective measurement of facial features, pupil responses, retinal electrical responses and autonomic nerve responses to light.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/15/2024
Locations: University of Iowa Health Care, Iowa City, Iowa
Conditions: Photophobia, Traumatic Brain Injury, Migraine
Register for Updates
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
NCT06173661
Recruiting
The goal of this clinical trial is to learn about how a migraine prevention medicine works for people who have migraines/headaches with their menstrual period. The study includes people ages 18 to 45 who have been diagnosed with migraine and who have a migraine with their menstrual period or those who have migraines with their menstrual period and at other times of the month as well. The main question the study aims to answer are: • Does fremanazemab, an injectable calcitonin gene-related pept... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
05/14/2024
Locations: Brigham and Women's Health Care Center, Chestnut Hill, Massachusetts
Conditions: Migraine, Menstrual Migraine, Menstrually Related Migraine
Register for Updates
Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain
NCT04930887
Recruiting
Exparel has a proven efficacy in providing pain relief for up to 72 hours with a single-dose administration at surgical sites. The study aims to evaluate the effectiveness of endoscopically-guided injection of Exparel (Bupivacaine) for the treatment of craniofacial pain. This study would be conducted in a prospective, randomized, double-blinded, placebo- controlled, and cross-over fashion. We aim to investigate whether the administration of Exparel (Bupivacaine) to the lateral nasal wall may pos... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/16/2024
Locations: Peter H Hwang, Stanford, California
Conditions: Craniofacial Pain, Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Sphenopalatine Ganglion Neuralgia, Paroxysmal Hemicrania
Register for Updates